Drugs / polyethylene glycol loxenatide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07558863 | Apr 2026 → Mar 2028 expected | diabetic autonomic neuropathy, type 2 diabetes mellitus | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | polyethylene glycol loxenatide | “Two specific GLP-1RAs are used in this study: semaglutide at 0.5 mg once weekly, or polyethylene glycol loxenatide at 0.2 mg once weekly.” NCT07558863 ↗ |